VERU INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
VERU INC. (VERU) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.93 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-10
- VERU INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-06-30 was $1.93, a 55.32% decline year-over-year.
- VERU INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- VERU INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-12-31 was $2.20, a 65.84% decline year-over-year.
- VERU INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $4.32, a 68.56% decline year-over-year.
- VERU INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $4.59, a 60.97% decline from fiscal 2024.
- VERU INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $11.76, a 111.89% increase from fiscal 2023.
- VERU INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $5.55.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.93 10-Q · filed 2026-08-10 | $1.97 10-Q · filed 2026-08-10 | ||||||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 | $2.20 10-Q · filed 2026-05-13 | ||||||
| 2025-12-31 | $2.20 10-Q · filed 2026-02-11 | |||||||
| 2025-09-30 | $4.59 10-K · filed 2025-12-17 | |||||||
| 2025-06-30 | $4.32 10-Q · filed 2026-08-10 | $4.59 10-Q · filed 2026-08-10 | ||||||
| 2025-03-31 | $3.88 10-Q · filed 2026-05-13 | $0.39 10-Q · filed 2025-05-08 | $6.28 10-Q · filed 2026-05-13 | $0.63 10-Q · filed 2025-05-08 | ||||
| 2024-12-31 | $6.44 10-Q · filed 2026-02-11 | $0.64 10-Q · filed 2025-02-13 | ||||||
| 2024-09-30 | $11.76 10-K · filed 2025-12-17 | $1.18 10-K · filed 2024-12-16 | ||||||
| 2024-06-30 | $13.74 10-Q · filed 2025-08-12 | $1.37 10-Q · filed 2024-08-08 | $12.16 10-Q · filed 2025-08-12 | $1.22 10-Q · filed 2024-08-08 | ||||
| 2024-03-31 | $0.44 10-Q · filed 2025-05-08 | $0.55 10-Q · filed 2025-05-08 | ||||||
| 2023-12-31 | $0.60 10-Q · filed 2025-02-13 | |||||||
| 2023-09-30 | $5.55 10-K · filed 2024-12-16 | |||||||
| 2023-06-30 | $1.12 10-Q · filed 2024-08-08 | $5.55 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |